SECURITIES AND EXCHANGE COMMISSION

FORM N-Q

Quarterly schedule of portfolio holdings of registered management investment company filed on Form N-Q

Filing Date: 2008-08-29 | Period of Report: 2008-06-30

SEC Accession No. 0001206774-08-001516

(HTML Version on secdatabase.com)

FILER

DELAWARE GROUP EQUITY FUNDS IV

CIK:778108| IRS No.: 000000000 | State of Incorp.:DE | Fiscal Year End: 0930

Type: N-Q | Act: 40 | File No.: 811-04413 | Film No.: 081047418

Mailing Address ONE COMMERCE SQ 2005 MARKET ST PHILADELPHIA PA 19103 **Business Address** 2005 MARKET ST ONE COMMERCE SQ PHILADELPHIA PA 19103 2152552127

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

FORM N-Q

QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY

Investment Company Act file number: 811-04413

Exact name of registrant as specified in charter: Delaware Group Equity Funds IV

Address of principal executive offices: 2005 Market Street

Philadelphia, PA 19103

Name and address of agent for service: David F. Connor, Esq.

2005 Market Street Philadelphia, PA 19103

Registrant's telephone number, including area code: (800) 523-1918

Date of fiscal year end: September 30

Date of reporting period: June 30, 2008

Item 1. Schedule of Investments.

Schedule of Investments (Unaudited)

Delaware Growth Opportunities Fund

June 30, 2008

	N 1 C	
	Number of	
	Shares	Value
Common Stock - 98.04%		
Basic Industry/Capital Goods - 13.23%		
Albemarle	67,000	\$ 2,673,970
*Allegheny Technologies	24,400	1,446,432
*†First Solar	14,600	3,983,172
Flowserve	50,200	6,862,340
Joy Global	80,400	6,096,732
†Mettler-Toledo International	49,800	4,724,028
*†Quanta Services	217,300	7,229,571
*Roper Industries	109,600	7,220,448
†Terex	85,500	4,392,135
		44,628,828

Business Services - 4.18%		
Dun & Bradstreet	48,800	4,276,832
Expeditors International Washington	122,900	5,284,700
†Fiserv	100,400	4,555,148
		14,116,680
Consumer Non-Durables - 11.97%		
*†Amazon.com	76,100	5,580,413
*†Dick's Sporting Goods	39,300	697,182
*†Dollar Tree	171,800	5,616,142
*Flowers Foods	252,600	7,158,684
*Guess	248,600	9,310,070
*†J. Crew Group	55,200	1,822,152
*†Ulta Salon Cosmetics & Fragrance	25,500	286,620
*†Urban Outfitters	317,700	9,909,063
		40,380,326
Consumer Services - 9.13%		
*Burger King Holdings	186,300	4,990,977
*†Chipotle Mexican Grill Class A	59,400	4,907,628
*Darden Restaurants	96,000	3,066,240
†DISH Network Class A	144,600	4,233,888
*Host Hotels & Resorts	153,170	2,090,771
International Game Technology	140,800	3,517,184
*Marriott International Class A	87,700	2,301,248
*Starwood Hotels & Resorts Worldwide	54,700	2,191,829
*†Wynn Resorts	42,900	3,489,915
		30,789,680
Energy - 13.87%		
*†Cameron International	98,000	5,424,300
†Core Laboratories	52,400	7,459,140
*†Geophysique-Veritas ADR	109,700	5,178,937
*†Helix Energy Solutions Group	112,500	4,684,500
*Helmerich & Payne	108,500	7,814,170
*†National Oilwell Varco	118,100	10,477,832
Smith International	69,200	5,753,288
		46,792,167
Financials - 6.96%		
*†Affiliated Managers Group	37,500	3,377,250
*†Interactive Brokers Group	156,700	5,034,771
*†IntercontinentalExchange	12,800	1,459,200
Invesco	151,400	3,630,572
*People's United Financial	241,500	3,767,400
SLM	211,400	4,090,590
*T. Rowe Price Group	37,500	2,117,625
		23,477,408
Health Care - 14.27% †Abraxis BioScience	48,731	3,092,469
†Affymetrix	70,400	724,416
*†APP Pharmaceuticals	311,100	5,201,592

##Atheros Communications 185,900 ##5 Networks 227,500 ##5 Networks 181,100 ##5 Networks 181,100 ##5 Networks 481,300 ##MEMC Electronic Materials 482,00 ##Microsomi 288,000 #*Omniture 31,700 #*6 Omniture 46,900 #*5 alse force.com 77,600 #*8 ykes Enterprises 270,600 #*8 ykes Enterprises 270,600 #*Total Common Stock (cost \$281,381,845) ##Iunt (J.B.) Transport Services 197,200 ##Iunt (J.B.) Transport Services 197,200 ##Omniture 70 tail Common Stock (cost \$281,381,845) ##Iunt (J.B.) Transport Services 197,200 ##Iunt (J.B.) Transport Servic	6,496,440 6,531,069 4,519,753 5,294,648 5,103,516 75,825,248 6,562,816 6,562,816 330,696,147 9,935,561 9,935,561 9,935,561 9,935,561 340,631,708
**15 Networks 227,500 **1 Juniper Networks 128,100 **Marvel Technology Group 485,300 **MEMC Electronic Materials 84,200 **Microsemi 258,000 **Omniture 351,700 **Pecision Castparts 46,900 **Sykas Enterprises 270,600 **Transportation - 1.95% **Hykke Enterprises **Hunt (J.B.) Transport Services 197,200 Total Common Stock (cost \$281,381,845) Principal Amount **Ederal Home Loan Bank 2.03% 7/1/08 \$ 9,935,261 Total Value of Securities Before Securities Lending Collateral - 100,98% (cost \$291,317,406) Number of Securities Lending Collateral - 22,75% Recurities Lending Collateral* - 22,75% Investment Companies Mellon GSL DBT II Collateral Fund 76,748,63 Total Securities Lending Collateral (cost \$76,748,630) Total Value of Securities Lending Collateral* - (22,75%) Collateral Fund Securities Lending Collateral* - (22,75%)	6,531,069 4,519,753 5,294,648 5,103,516 75,825,248 6,562,816 6,562,816 330,696,147 9,935,561 9,935,561 9,935,561 417,380,338 (76,748,630)
**FFS Networks 227,500 **Juniper Networks 128,100 **Marvell Technology Group 485,200 **MEMC Electronic Materials 84,200 **Microsemi 258,000 **Omniture 351,700 Precision Castparts 46,900 **salesforce com 77,600 **Sykes Enterprises 270,600 *Transportation - 1,95% **Hunt (J.B.) Transport Services 197,200 *Total Common Stock (cost \$281,381,845) *Federal Home Loan Bank 2,03% 7/1/08 \$ 9,935,561 *Total Discount Note (cost \$29,317,406) *Total Value of Securities Before Securities Lending Collateral - 100,98% (cost \$291,317,406) *Number of Shares Securities Lending Collateral* - 22,75% Investment Companies **Total Securities Lending Collateral Fund 76,748,63 Total Securities Lending Collateral Cost \$76,748,630)	6,531,069 4,519,753 5,294,648 5,103,516 75,825,248 6,562,816 6,562,816 330,696,147 9,935,561 9,935,561 9,935,561 417,380,338
**1FS Networks 227,500 **Juniper Networks 128,100 *Marvell Technology Group 485,300 **MEMC Electronic Materials 84,200 **Microsemi 258,000 **Offormiture 351,700 Precision Castparts 46,900 **Sykes Enterprises 270,600 **Sykes Enterprises 270,600 **Hunt (J.B.) Transport Services 197,200 **Transportation - 1-95% **Hunt (J.B.) Transport Services 197,200 **Transport Services **Principal Amount **Principal Amount <td>6,531,069 4,519,753 5,294,648 5,103,516 75,825,248 6,562,816 6,562,816 330,696,147 9,935,561 9,935,561 340,631,708</td>	6,531,069 4,519,753 5,294,648 5,103,516 75,825,248 6,562,816 6,562,816 330,696,147 9,935,561 9,935,561 340,631,708
**F5 Networks 227,500 **Juniper Networks 128,100 **Marvell Technology Group 485,300 *MEMC Electronic Materials 84,200 **Microsemi 258,000 **Omniture 351,700 Precision Castparts 46,900 **Spkse Enterprises 270,600 **Sykes Enterprises 270,600 *Transportation - 1,95% **Hunt (J.B.) Transport Services 197,200 *Total Common Stock (cost \$281,381,845) *Principal Amount *Discount Note - 2,94% \$ 9,935,561 *Total Value of Securities Before Securities Lending Collateral 100,98% (cost \$291,317,406) Number of Shares Securities Lending Collateral * - 22.75% Investment Companies Mellon GSL DBI II Collateral Fund 76,748,63	6,531,069 4,519,753 5,294,648 5,103,516 75,825,248 6,562,816 6,562,816 330,696,147 9,935,561 9,935,561 340,631,708
*FS Networks 227,500 **Juniper Networks 128,100 **Marvell Technology Group 485,300 **MEMC Electronic Materials 84,200 **Mile Celectronic M	6,531,069 4,519,753 5,294,648 5,103,516 75,825,248 6,562,816 6,562,816 330,696,147 9,935,561 9,935,561 340,631,708
*†FS Networks 227,500 *†Juniper Networks 128,100 †Marvell Technology Group 485,300 †MEMC Electronic Materials 84,200 *†Microsemi 258,000 *†Omniture 351,700 Precision Castparts 46,900 *†Sykes Enterprises 270,600 †Sykes Enterprises 270,600 *Hunt (J.B.) Transport Services 197,200 Total Common Stock (cost \$281,381,845) Principal Amount ≠Discount Note - 2.94% \$ 9,935,561 Total Discount Note (cost \$9,935,561) Total Value of Securities Before Securities Lending Collateral - 100.98% (cost \$291,317,406) Number of Shares Securities Lending Collateral + - 22.75% Investment Companies	6,531,069 4,519,753 5,294,648 5,103,516 75,825,248 6,562,816 6,562,816 330,696,147 9,935,561 9,935,561
**F5 Networks 227,500 **Juniper Networks 128,100 †Marvell Technology Group 485,300 †MEMC Electronic Materials 84,200 **Microsemi 258,000 **Omniture 351,700 Precision Castparts 46,900 **Sykes Enterprises 270,600 **Hunt (J.B.) Transport Services 197,200 Transportation - 1,95% *Hunt (J.B.) Transport Services 197,200 Total Common Stock (cost \$281,381,845) Principal Amount *Discount Note - 2,94% \$ 9,935,561 Total Discount Note (cost \$9,935,561) Total Value of Securities Before Securities Lending Collateral - 100,98% (cost \$291,317,406) Number of Shares Securities Lending Collateral - 22,75%	6,531,069 4,519,753 5,294,648 5,103,516 75,825,248 6,562,816 6,562,816 330,696,147 9,935,561 9,935,561
*YES Networks 227,500 *Juniper Networks 128,100 *Marvell Technology Group 485,300 *MEMC Electronic Materials 84,200 **Microsemi 258,000 **Omniture 351,700 Precision Castparts 46,900 **Sykes Enterprises 270,600 **Sykes Enterprises 270,600 *Transportation - 1.95% **Hunt (J.B.) Transport Services 197,200 *Total Common Stock (cost \$281,381,845) *Principal Amount *Discount Note - 2.94% \$ 9,935,561 *Total Discount Note (cost \$9,935,561) *Total Value of Securities Before Securities Lending Collateral - 100.98% **Total Value of Securities Before Securities Lending Collateral - 100.98% ***Cost \$291,317,406) **Number of Shares	6,531,069 4,519,753 5,294,648 5,103,516 75,825,248 6,562,816 6,562,816 330,696,147 9,935,561 9,935,561
**F5 Networks 227,500 **Juniper Networks 128,100 **Marvell Technology Group 485,300 *MEMC Electronic Materials 84,200 **Microsemi 258,000 **Omniture 351,700 Precision Castparts 46,900 **salesforce.com 77,600 **Sykes Enterprises 270,600 **Hunt (J.B.) Transport Services 197,200 Total Common Stock (cost \$281,381,845) Principal Amount *Discount Note - 2.94% **Cederal Home Loan Bank 2.03% 71/108 \$ 9,935,561 Total Value of Securities Before Securities Lending Collateral - 100.98% **Cost \$291,317,406 Number of	6,531,069 4,519,753 5,294,648 5,103,516 75,825,248 6,562,816 6,562,816 330,696,147 9,935,561 9,935,561
*FES Networks 227,500 †Juniper Networks 128,100 †Marvell Technology Group 485,300 †MEMC Electronic Materials 84,200 †Microsemi 258,000 †Omniture 351,700 Precision Castparts 46,900 †Sykes Enterprises 270,600 †Sykes Enterprises 270,600 *Hunt (J.B.) Transport Services 197,200 Total Common Stock (cost \$281,381,845) Principal Amount ≠Discount Note = 2.94% \$ 9,935,561 Total Value of Securities Before Securities Lending Collateral - 100.98%	6,531,069 4,519,753 5,294,648 5,103,516 75,825,248 6,562,816 6,562,816 330,696,147 9,935,561 9,935,561
*†F5 Networks 227,500 †Juniper Networks 128,100 †Marvell Technology Group 485,300 †MEMC Electronic Materials 84,200 † Microsemi 258,000 † Omniture 351,700 Precision Castparts 46,900 † Sykes Enterprises 270,600 † Sykes Enterprises 270,600 *Hunt (J.B.) Transport Services 197,200 Total Common Stock (cost \$281,381,845) Principal Amount *Discount Note - 2.94% Federal Home Loan Bank 2.03% 7/1/08 \$ 9,935,561 Total Discount Note (cost \$9,935,561)	6,531,069 4,519,753 5,294,648 5,103,516 75,825,248 6,562,816 6,562,816 330,696,147
*†F5 Networks 227,500 *†Juniper Networks 128,100 †Marvell Technology Group 485,300 †MEMC Electronic Materials 84,200 *†Microsemi 258,000 *†Omniture 351,700 Precision Castparts 46,900 *†Sykes Enterprises 270,600 *†Sykes Enterprises 270,600 Transportation - 1.95% *Hunt (J.B.) Transport Services 197,200 Total Common Stock (cost \$281,381,845) Principal Amount ≠Discount Note - 2.94% Federal Home Loan Bank 2.03% 7/1/08 \$ 9,935,561	6,531,069 4,519,753 5,294,648 5,103,516 75,825,248 6,562,816 6,562,816 330,696,147
*†F5 Networks 227,500 *†Juniper Networks 128,100 †Marvell Technology Group 485,300 †MEMC Electronic Materials 84,200 *†Microsemi 258,000 *†Omniture 351,700 Precision Castparts 46,900 *†Salesforce.com 77,600 *†Sykes Enterprises 270,600 Transportation - 1.95% *Hunt (J.B.) Transport Services 197,200 Total Common Stock (cost \$281,381,845) Principal Amount ≠Discount Note - 2.94% Federal Home Loan Bank 2.03% 7/1/08 \$ 9,935,561	6,531,069 4,519,753 5,294,648 5,103,516 75,825,248 6,562,816 6,562,816 330,696,147
*†F5 Networks 227,500 *†Juniper Networks 128,100 †Marvell Technology Group 485,300 †MEMC Electronic Materials 84,200 *†Microsemi 258,000 *†Omniture 351,700 Precision Castparts 46,900 *†salesforce.com 77,600 *†Sykes Enterprises 270,600 *Transportation - 1.95% *Hunt (J.B.) Transport Services 197,200 Total Common Stock (cost \$281,381,845) Principal Amount ≠Discount Note - 2.94%	6,531,069 4,519,753 5,294,648 5,103,516 75,825,248 6,562,816 6,562,816 330,696,147
*†F5 Networks 227,500 *†Juniper Networks 128,100 †Marvell Technology Group 485,300 †MEMC Electronic Materials 84,200 *†Omniture 351,700 Precision Castparts 46,900 *†Sykes Enterprises 270,600 *†Sykes Enterprises 270,600 *Hunt (J.B.) Transport Services 197,200 Total Common Stock (cost \$281,381,845)	6,531,069 4,519,753 5,294,648 5,103,516 75,825,248 6,562,816 6,562,816
*†FS Networks 227,500 ††Juniper Networks 128,100 †Marvell Technology Group 485,300 †MEMC Electronic Materials 84,200 *†Microsemi 258,000 *†Omniture 351,700 Precision Castparts 46,900 *†salesforce.com 77,600 *†Sykes Enterprises 270,600 *Transportation - 1.95% *Hunt (J.B.) Transport Services 197,200 Total Common Stock (cost \$281,381,845)	6,531,069 4,519,753 5,294,648 5,103,516 75,825,248 6,562,816 6,562,816
*†F5 Networks 227,500 *†Juniper Networks 128,100 †Marvell Technology Group 485,300 †MEMC Electronic Materials 84,200 *†Microsemi 258,000 *†Omniture 351,700 Precision Castparts 46,900 *†salesforce.com 77,600 *†Sykes Enterprises 270,600 *Transportation - 1.95% *Hunt (J.B.) Transport Services 197,200 Total Common Stock (cost \$281,381,845)	6,531,069 4,519,753 5,294,648 5,103,516 75,825,248 6,562,816 6,562,816
*†F5 Networks 227,500 *†Juniper Networks 128,100 †Marvell Technology Group 485,300 †MEMC Electronic Materials 84,200 *†Microsemi 258,000 *†Omniture 351,700 Precision Castparts 46,900 *†salesforce.com 77,600 *†Sykes Enterprises 270,600 *Transportation - 1.95% 197,200	6,531,069 4,519,753 5,294,648 5,103,516 75,825,248 6,562,816 6,562,816
*†F5 Networks 227,500 *†Juniper Networks 128,100 †Marvell Technology Group 485,300 †MEMC Electronic Materials 84,200 *†Microsemi 258,000 *†Omniture 351,700 Precision Castparts 46,900 *†salesforce.com 77,600 *†Sykes Enterprises 270,600 *Transportation - 1.95% *Hunt (J.B.) Transport Services 197,200	6,531,069 4,519,753 5,294,648 5,103,516 75,825,248 6,562,816 6,562,816
*†F5 Networks 227,500 *†Juniper Networks 128,100 †Marvell Technology Group 485,300 †MEMC Electronic Materials 84,200 *†Microsemi 258,000 *†Omniture 351,700 Precision Castparts 46,900 *†salesforce.com 77,600 *†Sykes Enterprises 270,600	6,531,069 4,519,753 5,294,648 5,103,516 75,825,248
*†F5 Networks 227,500 *†Juniper Networks 128,100 †Marvell Technology Group 485,300 †MEMC Electronic Materials 84,200 *†Microsemi 258,000 *†Omniture 351,700 Precision Castparts 46,900 *†salesforce.com 77,600 *†Sykes Enterprises 270,600	6,531,069 4,519,753 5,294,648 5,103,516 75,825,248
*†F5 Networks 227,500 *†Juniper Networks 128,100 †Marvell Technology Group 485,300 †MEMC Electronic Materials 84,200 *†Microsemi 258,000 *†Omniture 351,700 Precision Castparts 46,900 *†salesforce.com 77,600 *†Sykes Enterprises 270,600	6,531,069 4,519,753 5,294,648 5,103,516
*†F5 Networks 227,500 *†Juniper Networks 128,100 †Marvell Technology Group 485,300 †MEMC Electronic Materials 84,200 *†Microsemi 258,000 *†Omniture 351,700 Precision Castparts 46,900 *†salesforce.com 77,600	6,531,069 4,519,753 5,294,648
*†F5 Networks 227,500 *†Juniper Networks 128,100 †Marvell Technology Group 485,300 †MEMC Electronic Materials 84,200 *†Microsemi 258,000 *†Omniture 351,700 Precision Castparts 46,900	6,531,069 4,519,753
*†F5 Networks 227,500 *†Juniper Networks 128,100 †Marvell Technology Group 485,300 †MEMC Electronic Materials 84,200 *†Microsemi 258,000 *†Omniture 351,700	6,531,069
*†F5 Networks 227,500 *†Juniper Networks 128,100 †Marvell Technology Group 485,300 †MEMC Electronic Materials 84,200 *†Microsemi 258,000	
*†F5 Networks 227,500 *†Juniper Networks 128,100 †Marvell Technology Group 485,300 †MEMC Electronic Materials 84,200	6,496,440
*†F5 Networks 227,500 *†Juniper Networks 128,100 †Marvell Technology Group 485,300	
*†F5 Networks 227,500 *†Juniper Networks 128,100	5,181,668
*†F5 Networks 227,500	8,570,398
	2,841,258
*†Atheros Communications 185,900	6,465,550
	5,577,000
*†ANSYS 196,200	9,244,944
*†American Tower Class A	5,124,925
*†Akamai Technologies 140,100	4,874,079
Technology - 22.48%	40,122,994
174,000	48,122,994
*†ResMed 194,800	6,962,152
*†Regeneron Pharmaceuticals 168,800	2,437,472
*Perrigo 130,900 *Quest Diagnostics 98,400	4,769,448
· · · · · · · · · · · · · · · · · · ·	4,158,693
*†ImClone Systems 86,200 †Medco Health Solutions 136,100	3,487,652 6,423,920
*†Express Scripts 38,900	2,439,808
†Barr Pharmaceuticals 117,700	5,305,916
†Applera - Celera Group 274,600	3,119,456

- †Non income producing.
- ≠The rate shown is the effective yield at the time of purchase.
- *Fully or partially on loan.
- **See Note 3 in "Notes".
- ▲ Includes \$76,198,942 of securities loaned.

ADR - American Depositary Receipt

Notes

1. Significant Accounting Policies

The following accounting policies are in accordance with U.S. generally accepted accounting principles and are consistently followed by the Delaware Group Equity Funds IV - Delaware Growth Opportunities Fund (Fund).

Security Valuation - Equity securities, except those traded on the Nasdaq Stock Market, Inc. (Nasdaq), are valued at the last quoted sales price as of the time of the regular close of the New York Stock Exchange (NYSE) on the valuation date. Securities traded on the Nasdaq are valued in accordance with the Nasdaq Official Closing Price, which may not be the last sales price. If on a particular day an equity security does not trade, then the mean between the bid and asked prices will be used. Short-term debt securities having less than 60 days to maturity are valued at amortized cost, which approximates market value. Securities lending collateral, which is invested in a collective investment vehicle (Collective Trust), is valued at unit value per share. Generally, other securities and assets for which market quotations are not readily available are valued at fair value as determined in good faith under the direction of the Fund's Board of Trustees (Board). In determining whether market quotations are readily available or fair valuation will be used, various factors will be taken into consideration, such as market closures, aftermarket trading or significant events after local market trading (e.g., government actions or pronouncements, trading volume or volatility on markets, exchanges among dealers, or news events).

In September 2006, the Financial Accounting Standards Board (FASB) issued FASB Statement No. 157 "Fair Value Measurements" (FAS 157). FAS 157 establishes a framework for measuring fair value in U.S. generally accepted accounting principles, clarifies the definition of fair value within that framework, and expands disclosures about the use of fair value measurements. FAS 157 is intended to increase consistency and comparability among fair value estimates used in financial reporting. FAS 157 is effective for fiscal years beginning after November 15, 2007. Management does not expect the adoption of FAS 157 to have a material impact on the amounts reported in the financial statements.

Federal Income Taxes - The Fund intends to continue to qualify for federal income tax purposes as a regulated investment company under Subchapter M of the Internal Revenue Code of 1986, as amended, and make the requisite distributions to shareholders. Accordingly, no provision for federal income taxes has been made in the financial statements.

Effective March 31, 2008, the Fund adopted FASB Interpretation No. 48 "Accounting for Uncertainty in Income Taxes" (FIN 48). FIN 48 provides guidance for how uncertain tax positions should be recognized, measured, presented, and disclosed in the financial statements. FIN 48 requires the evaluation of tax positions taken or expected to be taken in the course of preparing the Fund's tax returns to determine whether the tax positions are "more-likely-than-not" of being sustained by the applicable tax authority. Tax positions not deemed to meet the more-likely-than-not threshold are recorded as a tax benefit or expense in the current year. The adoption of FIN 48 did not result in the recording of any tax benefit or expense in the current period.

Class Accounting - Investment income, common expenses and realized and unrealized gain (loss) on investments are allocated to the various classes of the Fund on the basis of daily net assets of each class. Distribution expenses relating to a specific class are charged directly to that class.

Repurchase Agreements - The Fund may invest in a pooled cash account along with members of the Delaware Investments[®] Family of Funds pursuant to an exemptive order issued by the Securities and Exchange Commission. The aggregate daily balance of the pooled cash account is invested in repurchase agreements secured by obligations of the U.S. government. The respective collateral is held by the Fund's custodian bank until the maturity of the respective repurchase agreements. Each repurchase agreement is at least 102% collateralized. However, in the event of default or bankruptcy by the counterparty to the agreement, realization of the collateral may be subject to legal proceedings. At June 30, 2008, the Fund held no investments in repurchase agreements.

Use of Estimates – The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Other - Expenses directly attributable to the Fund are charged directly to the Fund. Other expenses common to various funds within the Delaware Investments. Family of Funds are generally allocated amongst such funds on the basis of average net assets. Management fees and some other expenses are paid monthly. Security transactions are recorded on the date the securities are purchased or sold (trade date) for financial reporting purposes. Costs used in calculating realized gains and losses on the sale of investment securities are those of the specific securities sold. Dividend income is recorded on the ex-dividend date and interest income is recorded on the accrual basis. Distributions received from investments in Real Estate Investment Trusts (REITs) are recorded as dividend income on the ex-dividend date, subject to reclassification upon notice of the character of such distribution by the issuer. The Fund declares and pays dividends from net investment income and distributions from net realized gain on investments, if any, annually.

2. Investments

At June 30, 2008, the cost of investments for federal income tax purposes has been estimated since the final tax characteristics cannot be determined until fiscal year end. At June 30, 2008, the cost of investments and unrealized appreciation (depreciation) for the Fund was as follows:

Cost of investments	\$370,955,305
Aggregate unrealized appreciation	67,411,178
Aggregate unrealized depreciation	(20,986,145)
Net unrealized appreciation	\$46,425,033

3. Securities Lending

The Fund, along with other funds in the Delaware Investments[®] Family of Funds, may lend its securities pursuant to a security lending agreement (Lending Agreement) with the Bank of New York Mellon (BNY Mellon). With respect to each loan, if the aggregate market value of the collateral held on any business day is less than the aggregate market value of the securities which are the subject of such loan, the borrower will be notified to provide additional collateral not less than the applicable collateral requirement. Cash collateral received is invested in a Collective Trust established by BNY Mellon for the purpose of investment on behalf of clients participating in its securities lending programs. The Collective Trust invests in fixed income securities, with a weighted average maturity not to exceed 90 days, rated in one of the top three tiers by Standard & Poor's Ratings Group (S&P) or Moody's Investors Service, Inc. (Moody's) or repurchase agreements collateralized by such securities. The Fund can also accept U.S. government securities and letters of credit (non-cash collateral) in connection with securities loans. In the event of default or bankruptcy by the lending agent, realization and/or retention of the collateral may be subject to legal proceedings. In the event the borrower fails to return loaned securities and the collateral received is insufficient to cover the value of the loaned securities and provided such collateral shortfall is not the result of investment losses, the lending agent has agreed to pay the amount of the shortfall to the Fund, or at the discretion of the lending agent, replace the loaned securities. The Fund continues to record dividends or interest, as applicable, on the securities loaned and is subject to change in value of the securities loaned that may occur during the term of the loan. The Fund has the right under the Lending Agreement to recover the securities from the borrower on demand. With respect to security loans collateralized by cash collateral, the earnings from th

At June 30, 2008, the value of securities on loan was \$76,198,942, for which the Fund received collateral, comprised of non-cash collateral valued at \$2,217,589, and cash collateral of \$76,748,630. Investments purchased with cash collateral are presented on the schedule of investments under the caption "Securities Lending Collateral."

4. Credit and Market Risk

The Fund invests a significant portion of its assets in small- and mid-sized companies and may be subject to certain risks associated with ownership of securities of such companies. Investments in small- or mid-sized companies may be more volatile than investments in larger companies for a number of reasons, which include more limited financial resources or a dependence on narrow product lines.

The Fund may invest in REITs and is subject to some of the risks associated with that industry. If the Fund holds real estate directly as a result of defaults or receives rental income directly from real estate holdings, its tax status as a regulated investment company may be jeopardized. There were no direct real estate holdings during the period ended June 30, 2008. The Fund's REIT holdings are also affected by interest rate changes, particularly if the REITs it holds use floating rate debt to finance their ongoing operations.

The Fund may invest up to 15% of its net assets in illiquid securities, which may include securities with contractual restrictions on resale, securities exempt from registration under Rule 144A of the Securities Act of 1933, as amended, and other securities which may not be readily marketable. The relative illiquidity of these securities may impair the Fund

from disposing of them in a timely manner and at a fair price when it is necessary or desirable to do so. While maintaining oversight, the Fund's Board has delegated to Delaware Management Company, a series of Delaware Management Business Trust, the day-to-day functions of determining whether individual securities are liquid for purposes of the Fund's limitation on investments in illiquid assets. Securities eligible for resale pursuant to Rule 144A, which are determined to be liquid, are not subject to the Fund's 15% limit on investments in illiquid securities. As of June 30, 2008, there were no Rule 144A securities and no securities have been determined to be illiquid under the Fund's Liquidity Procedures.

Schedule of Investments (Unaudited)

Delaware Global Real Estate Securities Fund

June 30, 2008

	Number of	Value
	Shares	(U.S. \$)
Common Stock - 93.72%∆		
Australia - 8.53%		
Goodman Group	10,151	\$ 30,051
GPT Group	14,241	30,289
Stockland	5,067	26,165
Valad Property Group	18,915	12,141
Westfield Group	6,198	96,671
		195,317
Austria - 1.22%		
†Conwert Immobilien Invest	1,626	27,957
		27,957
Brazil - 1.50%		
†BR Malls Participacoes	3,607	34,209
	,	34,209
Canada - 2.51%		
Boardwalk Real Estate Investment Trust	177	6,619
RioCan Real Estate Investment Trust	2,616	50,925
	,	57,544
China - 0.72%		
Shimao Property Holdings	14,415	16,546
	, .	16,546
France - 5.84%		
Fonciere Des Regions	270	33,074
Unibail-Rodamco	435	100,627
Caroni Industry	150	133,701
Greece - 1.26%		155,701
Babis Vovos International Construction	875	28,794
Daois vovos international Constituction	0/3	28,794
Hong Kong - 13.30%		20,774
China Overseas Land & Investment	18,685	29,523
Hang Lung Group	9,000	39,995
Henderson Land Development	10,000	62,330
Hysan Development	4,200	11,527
Link REIT	11,016	25,092
Midland Holdings	23,400	14,525
ividiand Holdings	23,400	14,323

New World China Land	14,100	7,306
New World Development	16,000	32,586
Sun Hung Kai Properties	6,000	81,414
		304,298
Italy - 0.70%		
Beni Stabili	16,050	15,921
Japan - 12.93%		15,921
Aeon Mall	1,042	30,819
Japan Prime Realty Investment	4	11,831
Kenedix Realty Investment	2	11,868
Mitsubishi Estate	5,000	114,444
Mitsui Fudosan	4,000	85,527
NTT Urban Development	13	17,021
Tokyu REIT	3	24,387
TOKYU KETI	3	
Malauria 1000/		295,89
Malaysia - 1.98%	10,000	0.210
Bandar Raya Developments	18,000	9,310
KLCC Property Holdings	18,450	15,359
Sunway City	25,433	20,548
		45,217
Norway - 0.57%		
Norwegian Property	2,822	13,132
		13,132
Singapore - 2.60%		
Ascendas Real Estate Investment Trust	14,900	24,201
CapitaMall Trust	6,000	13,185
Suntec Real Estate Investment Trust	22,000	21,989
		59,375
Sweden - 0.50%		
Castellum	1,200	11,459
		11,459
United Kingdom - 6.32%	100	15.504
British Land	1,261	17,784
Hammerson	3,435	61,102
Land Securities Group	2,678	65,774
		144,660
United States - 33.24%		
Alexandria Real Estate Equities	350	34,068
AMB Property	385	19,396
AvalonBay Communities	200	17,832
Boston Properties	350	31,577
BRE Properties	300	12,984
Brookfield Properties	1,757	31,551
Camden Property Trust	150	6,639
Developers Diversified Realty	400	13,884
Digital Realty Trust	480	19,637
Duke Realty	550	12,348

Entertainment Properties Trust	100	4,944
Equity Residential	550	21,049
Essex Property Trust	100	10,650
Federal Realty Investment Trust	200	13,800
General Growth Properties	1,050	36,781
НСР	700	22,267
Health Care REIT	450	20,025
Highwoods Properties	250	7,855
Home Properties	250	12,015
Host Hotels & Resorts	1,850	25,253
Kimco Realty	1,000	34,519
Kite Realty Group Trust	750	9,375
Liberty Property Trust	400	13,260
Macerich	250	15,533
Mack-Cali Realty	250	8,543
Macquarie Infrastructure	150	3,794
Marriott International Class A	250	6,560
ProLogis	685	37,229
Public Storage	400	32,316
Ramco-Gershenson Properties Trust	450	9,243
Regency Centers	350	20,692
Senior Housing Properties Trust	500	9,765
Simon Property Group	1,100	98,878
SL Green Realty	180	14,890
Ventas	650	27,671
Vornado Realty Trust	500	43,999
		760,822
Total Common Stock (cost \$2,585,376)		2,144,849
Right - 0.00%		
Norwegian Property	2,291	36
Total Right (cost \$0)		36
	Principal	
	Amount	
≠Discount Note - 6.16%		
Federal Home Loan Bank 2.03% 7/1/08	\$ 141,008	141,008
Total Discount Note (cost \$141,008)		141,008
Total Value of Securities - 99.88%		
(cost \$2,726,384)		2,285,893
Receivables and Other Assets Net of Liabilities (See Notes) - 0.12%		2,699

 $\Delta Securities$ have been classified by country of origin.

 \dagger Non income producing security.

≠The rate shown is the effective yield at the time of purchase.

Net Assets Applicable to 358,388 Shares Outstanding - 100.00%

REIT - Real Estate Investment Trust

\$2,288,592

Notes

1. Significant Accounting Policies

The following accounting policies are in accordance with U.S. generally accepted accounting principles and are consistently followed by Delaware Group Equity Funds IV - Delaware Global Real Estate Securities Fund (Fund).

Security Valuation - Equity securities, except those traded on the Nasdaq Stock Market, Inc. (Nasdaq), are valued at the last quoted sales price as of the time of the regular close of the New York Stock Exchange (NYSE) on the valuation date. Securities traded on the Nasdaq are valued in accordance with the Nasdaq Official Closing Price, which may not be the last sales price. If on a particular day an equity security does not trade, then the mean between the bid and asked prices will be used. Securities listed on a foreign exchange are valued at the last quoted sales price on the valuation date. Short-term debt securities having less than 60 days to maturity are valued at amortized cost, which approximates market value. Generally, other securities and assets for which market quotations are not readily available are valued at fair value as determined in good faith under the direction of the Fund's Board of Trustees (Board). In determining whether market quotations are readily available or fair valuation will be used, various factors will be taken into consideration, such as market closures, or with respect to foreign securities, aftermarket trading or significant events after local market trading (e.g., government actions or pronouncements, trading volume or volatility on markets, exchanges among dealers, or news events).

In September 2006, the Financial Accounting Standards Board (FASB) issued FASB Statement No. 157 "Fair Value Measurements" (Statement 157). Statement 157 establishes a framework for measuring fair value in U.S. generally accepted accounting principles, clarifies the definition of fair value within that framework, and expands disclosures about the use of fair value measurements. Statement 157 is intended to increase consistency and comparability among fair value estimates used in financial reporting. Statement 157 is effective for fiscal years beginning after November 15, 2007. Management does not expect the adoption of Statement 157 to have a material impact on the amounts reported in the financial statements.

Federal Income Taxes - The Fund intends to qualify for federal income tax purposes as a regulated investment company under Subchapter M of the Internal Revenue Code of 1986, as amended, and make the requisite distributions to shareholders. Accordingly, no provision for federal income taxes has been made in the financial statements.

Class Accounting - Investment income, common expenses and realized and unrealized gain (loss) on investments are allocated to the various classes of the Fund on the basis of daily net assets of each class. Distribution expenses relating to a specific class are charged directly to that class.

Repurchase Agreement - The Fund may invest in a pooled cash account along with members of the Delaware Investments Family of Funds pursuant to an exemptive order issued by the Securities and Exchange Commission. The aggregate daily balance of the pooled cash account is invested in repurchase agreements secured by obligations of the U.S government. The respective collateral is held by the Fund's custodian bank until the maturity of the respective repurchase agreements. Each repurchase agreement is at least 102% collateralized. However, in the event of default or bankruptcy by the counterparty to the agreement, realization of the collateral may be subject to legal proceedings. At June 30, 2008, the Fund held no investments in repurchase agreements.

Foreign Currency Transactions - Transactions denominated in foreign currencies are recorded at the prevailing exchange rates on the valuation date. The value of all assets and liabilities denominated in foreign currencies is translated into U.S. dollars at the exchange rate of such currencies against the U.S. dollar daily. Transaction gains or losses resulting from changes in exchange rates during the reporting period or upon settlement of the foreign currency transaction are reported in operations for the current period. The Fund does not isolate that portion of realized gains and losses on investments which are due to changes in foreign exchange rates from that which are due to changes in market prices. The Fund reports certain foreign currency related transactions as components of realized gains (losses) for financial reporting purposes, where such components are treated as ordinary income (loss) for federal income tax purposes.

Use of Estimates – The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Other - Expenses directly attributable to the Fund are charged directly to the Fund. Other expenses common to various funds within the Delaware Investments. Family of Funds are generally allocated amongst such funds on the basis of average net assets. Management fees and some other expenses are paid monthly. Security transactions are recorded on the date the securities are purchased or sold (trade date) for financial reporting purposes. Costs used in calculating realized gains and losses on the sale of investment securities are those of the specific securities sold. Dividend income is recorded on the ex-dividend date and interest income is recorded on the accrual basis. Distributions received from investments in Real Estate Investment Trusts (REITs) are recorded as dividend income on the ex-dividend date, subject to reclassification upon notice of the character of such

distribution by the issuer. Foreign dividends are also recorded on the ex-dividend date or as soon after the ex-dividend date that the Fund is aware of such dividends, net of all non-rebatable tax withholdings. Withholding taxes on foreign dividends have been recorded in accordance with the Fund's understanding of the applicable country's tax rules and rates. The Fund declares and pays dividends from net investment income and distributions from net realized gain on investments, if any, annually.

2. Investments

At June 30, 2008, the cost of investments for federal income tax purposes has been estimated since final tax characteristics cannot be determined until the fiscal year end. At June 30, 2008, the cost of investments and unrealized appreciation (depreciation) for the Fund were as follows:

Cost of investments	\$2,779,798
Aggregate unrealized appreciation	\$4,590
Aggregate unrealized depreciation	(498,495)
Net unrealized depreciation	\$(493,905)

3. Credit and Market Risk

Some countries in which the Fund may invest require governmental approval for the repatriation of investment income, capital or the proceeds of sales of securities by foreign investors. In addition, if there is deterioration in a country's balance of payments for other reasons, a country may impose temporary restrictions on foreign capital remittances abroad

The securities exchanges of certain foreign markets are substantially smaller, less liquid and more volatile than the major securities markets in the United States. Consequently, acquisition and disposition of securities by the Fund may be inhibited. In addition, a significant portion of the aggregate market value of equity securities listed on the major securities exchanges in emerging markets are held by a smaller number of investors. This may limit the number of shares available for acquisition or disposition by the Fund.

The Fund concentrates its investments in the real estate industry and is subject to some of the risks associated with that industry. If the Fund holds real estate directly as a result of defaults or receives rental income directly from real estate holdings, its tax status as a regulated investment company may be jeopardized. This Fund is also affected by interest rate changes, particularly if the real estate investment trusts it holds use floating rate debt to finance their ongoing operations. Its investments may also tend to fluctuate more in value than a fund that invests in a broader range of industries.

The Fund may invest up to 15% of its net assets in illiquid securities, which may include securities with contractual restrictions on resale, securities exempt from registration under Rule 144A of the Securities Act of 1933, as amended, and other securities which may not be readily marketable. The relative illiquidity of these securities may impair the Fund from disposing of them in a timely manner and at a fair price when it is necessary or desirable to do so. While maintaining oversight, the Fund's Board has delegated to Delaware Management Company, a series of Delaware Management Business Trust, the day-to-day functions of determining whether individual securities are liquid for purposes of the Fund's limitation on investments in illiquid assets. Securities eligible for resales pursuant to Rule 144A, which are determined to be liquid, are not subject to the Fund's 15% limit on investments in illiquid securities. As of June 30, 2008, there were no Rule 144A securities and no securities have been determined to be illiquid under the Fund's Liquidity Procedures.

Schedule of Investments (Unaudited)

Delaware Healthcare Fund

June 30, 2008

	Number of	
	Shares	Value
Common Stock - 95.84%□		
Biotechnology - 20.16%		
†Abraxis BioScience	1,200	\$76,152
†AVANIR Pharmaceuticals Class A	4,500	4,500
†Cardiome Pharma	800	7,040

Gommé (manumonicé) 2,00 19,12 Finamonicés 2,00 2,90 Finamonicés 30 6,50 Financian 30 6,50 Financian 1,00 10,40 Financian 1,00 10,40 Mediar 3,50 1,50 Menogram Routeres 1,50 1,50 OSP Prantacturich 1,50 1,50 OSP Prantacturich 1,50 1,50 OSP Prantacturich 1,50 1,50 Progue Shammacutich 1,50 2,50 Progue Shammacutich 1,50 2,50 Respector Hammacutich 1,00 5,60 Respector Hammacutich 1,00 5,60 Progue Shammacutich 1,00 5,60 Progue Shammacutich 1,00 5,60 Part Themperaturich 1,00 5,60 Part Paramacutich 1,00 5,60 Part Paramacutich 1,00 5,60 Part Paramacutich 1,0 5,60	†Cougar Biotechnology	400	9,532
Immunoceleck 7,000	†Elan ADR	300	10,665
Interpretameneutricits 700 2.98 Interfedited 500 6.80 Interfedited 520 1.00 Medicac 5.29 3.00 Monogram Bisociacies 1.00 1.68 Outras Bisophameaceticis 1.00 2.91 OSP Parameaceticis 2.00 10,60 Proposito Pharmaceticis 2.00 10,60 Proposito Pharmaceticis 2.00 10,60 Proposito Pharmaceticis 2.00 5.00 Regenerar Pharmaceticis 2.00 5.00 Securacy Pharmaceticis 2.00 5.00 Securacy Pharmaceticis 2.00 5.00 Securacy Pharmaceticis 2.00 5.00 Securacy Pharmaceticis 2.00 5.00 Turbo Pharmac	†Genmab	240	9,172
Intentifusion 50 6,86 Lyand Parametericks Closs B 4,00 10,408 Members 5,75 18,88 Members 1,50 1,60 One Displantmentich 1,80 2,80 OSI Plantmenetrich 4,80 19,33 OSI Plantmenetrich 4,80 19,33 Popuse Plantmenetrich 1,50 2,30 Regener Plantmenetrich 1,50 2,30 Regener Plantmenetrich 1,50 2,30 Regener Plantmenetrich 2,00 2,60 Regener Plantmenetrich 2,00 2,60 Seutzer Plantmenetrich 2,00 2,60 Special Plantmenetrich 2,00 2,60 Valle Plantmenetrich 2,00 2,60 Special Plantmenetrich 2,00 2,60 Part Lan	†Immunomedics	7,000	14,910
Signal Pharmacunicals Class 1	†Inspire Pharmaceuticals	700	2,996
Medicanes 5,580 38,088 Monogran Biosciences 1,500 1,500 Orners Reprincenticals 1,800 1,901 OSE Plantaceuticals 4,800 198,335 Propertic Plantaceuticals 1,500 2,280 Regeneror Plantaceuticals 2,000 1,290 Regeneror Plantaceuticals 200 2,682 Security Plantaceuticals 200 2,682 Security Plantaceuticals 200 2,682 Security Plantaceuticals 200 2,682 System Plantaceuticals 200 2,682 System Plantaceuticals 2,000 2,682 Trabios Plantaceuticals 2,000 2,682 Trabios Plantaceuticals 2,000 2,682 Trabios Plantaceuticals 2,000 2,682 Trabios Plantaceutical 2,000 2,682 Trabios Plantaceutical 2,000 2,682 Trabios Plantaceutical 2,000 2,682 Trabios Plantaceutical 2,000 2,682 Allegactica Plantaceutical	†InterMune	500	6,560
Monogam Biosciences 1,50 1,50 Oterna Bioplamaceuticula 1,80 2,819 Oterna Bioplamaceuticula 4,800 19,813 Peniard Pharmaceuticula 2,50 10,000 Polizieria Pharmaceuticula 50 1,290 Polizieria Pharmaceuticula 2,00 5,000 Sesciera Pharmaceuticula Class A 2,00 5,000 Sistana Pharmaceuticula Class A 1,00 7,10 Sistana Pharmaceuticula Class A 2,00 6,80 Valla Pharmaceuticula 1,00 7,10 Palamaceuticula 2,00 6,80 Valla Pharmaceuticula 2,00 6,80 Valla Pharmaceuticula ADR 2,00 6,80 VAIL Boyanmaceuticula ADR 2,00 1,80 VAIL Boyanmaceuticula ADR 1,00 7,945 Arregue Cheuticular Strate 1,50 7,945 Arregue Cheuticular Strategia 1,50 7,945 Arregue Cheuticular Strategia 1,50 1,50 Arregue Cheuticular Strategia 1,50 1,50	†Ligand Pharmaceuticals Class B	4,000	10,400
60eris Biopharmaceuticals 1,850 29,119 OSP Pharmaceuticals 2,500 10,600 Processing Pharmaceuticals 1,500 23,805 Regeneron Pharmaceuticals 900 12,906 Secange Pharmaceuticals 900 2,805 Secange Pharmaceuticals 900 5,800 Secange Pharmaceuticals 900 5,800 Secange Pharmaceuticals 900 5,800 Pinabin Pharmaceuticals 1,600 7,136 Pinabin Pharmaceuticals 2,500 6,850 Pinabin Pharmaceuticals 2,500 6,850 Pinabin Pharmaceuticals 1,600 7,136 Pinabin Pharmaceutical 2,500 6,850 Pinabin Pharmaceutical 2,500 6,850 Pinabin Pharmaceutical 1,500 7,900 Pinabin Pharmaceutical 1,500 7,915 Abbort Laborative 1,500 7,915 Pinabin Pharmaceutical 1,500 7,915 Assignation 1,000 1,915 Assignation 1,000<	†Medarex	5,750	38,008
60eris Biopharmaceuticals 1,850 29,119 OSP Pharmaceuticals 2,500 10,600 Processing Pharmaceuticals 1,500 23,805 Regeneron Pharmaceuticals 900 12,906 Secange Pharmaceuticals 900 2,805 Secange Pharmaceuticals 900 5,800 Secange Pharmaceuticals 900 5,800 Secange Pharmaceuticals 900 5,800 Pinabin Pharmaceuticals 1,600 7,136 Pinabin Pharmaceuticals 2,500 6,850 Pinabin Pharmaceuticals 2,500 6,850 Pinabin Pharmaceuticals 1,600 7,136 Pinabin Pharmaceutical 2,500 6,850 Pinabin Pharmaceutical 2,500 6,850 Pinabin Pharmaceutical 1,500 7,900 Pinabin Pharmaceutical 1,500 7,915 Abbort Laborative 1,500 7,915 Pinabin Pharmaceutical 1,500 7,915 Assignation 1,000 1,915 Assignation 1,000<	†Monogram Biosciences	1,500	1,650
OS Pharmaceuticals 4,800 198,335 Portical Pharmaceuticals 1,500 23,800 Regeners Pharmaceuticals 900 12,966 Sovices Pharmaceuticals 900 5,605 Sovices Pharmaceuticals 200 5,605 Systems Pharmaceuticals 900 5,406 "Stream Pharmaceuticals 100 6,713 "Stream Pharmaceuticals 100 6,713 "Path Pharmaceuticals 1,00 7,136 "Path Pharmaceuticals 2,00 6,80 "Path Pharmaceuticals 2,00 6,80 "Path Pharmaceuticals 1,00 7,136 "Path Pharmaceuticals 2,00 6,80 "Path Pharmaceuticals 2,00 6,80 "PATH Shopharmaceuticals 2,00 6,80 "PATH Shopharmaceuticals 1,00 7,845 About Laboratoris 1,00 2,81 About Laboratoris 1,00 6,10 About Laboratoris 1,00 6,20 Clicase Shiff Michical Products - 3,35% 6,20			
Pointed Pharmaceuticals 2,500 10,000 Progenits Pharmaceuticals 1,500 22,906 Shirten Pharmaceuticals 200 5,006 Shirten Pharmaceuticals 200 5,006 Shirten Pharmaceuticals 200 5,006 Shirten Pharmaceuticals 700 96 Flance Pharmaceuticals 1,000 7,136 Vanda Pharmaceuticals 2,000 5,000 Vanda Pharmaceuticals 2,000 9,000 EVEL Bropharmaceuticals ADR 2,500 9,000 EVEL Bropharmaceutical ADR 2,500 9,000 Brock Chip Medical Products 37,58% 3,000 79,455 Brock Chip Medical Products 37,58% 3,000 150,000 Martina Chia 3,000 150,000 Arta Zenca 788 34,049 Strates Shapes 1,000 45,046 Generace Chia 1,000 45,046 Generace Chia 1,000 45,046 Generace Chia 1,000 45,046 Generace Chia 1,000	†OSI Pharmaceuticals		
Progenics Pharmaceuticals 1,500 23,005 Regeneror Pharmaceuticals 90 15,00 Sevient Pharmaceuticals 200 5,00 Sevient Pharmaceuticals 2,00 2,825 Syring Pharmaceuticals 90 5,00 Thubin Pharmaceuticals 1,00 7,136 Thubin Pharmaceuticals 1,600 7,136 Wanda Pharmaceutical ADR 2,00 6,800 Tyrun Giornetics 1,500 1,600 Tyrun Giornetics 1,500 1,600 Tyrun Giornetics 1,500 7,945 Appear 3,00 15,901 Ayun Giornetics 1,500 7,945 Abutta Laboratical ADR 1,100 2,283 Chean Chy Medical Products 37,58% 1,100 3,600 Tyrun Giornetics 1,100 3,600 <	†Poniard Pharmaceuticals		
Repenerun Pharmaceuticals 900 1296 Saviera Pharmaceuticals 200 5,606 Riscampor Pharmaceuticals 900 5,400 Pittar Pharmaceuticals 900 5,400 Pittar Pharmaceuticals 1,600 7,136 Vanda Pharmaceuticals 2,000 6,800 PATT Biopharmaceuticals ADR 2,500 9,600 PATT Biopharmaceuticals ADR 2,500 9,600 PATT Biopharmaceutical SAR 1,500 1,263 PATT Biopharmaceutical SAR 2,500 9,600 PATT Biopharmaceutical SAR 1,500 1,263 PATT Biopharmaceutical SAR 1,500 1,263 Bioth Chip Medical Products - 37,5876 1 1,500 1,501 Abbot Laboratories 1,500 1,501			
Saveanp Pharmaceutical Sus A 2,00 5,06 Sixeanp Pharmaceuticals 2,90 2,828 Fythus Pharmaceuticals 70 66 17 Tubion Pharmaceuticals 1,00 2,736 17 Tubion Pharmaceuticals 1,00 2,80 PATLAB Biopharmaceuticals ADR 2,50 9,600 PATLAB Dispharmaceuticals ADR 2,50 9,600 PATLAB Dispharmaceuticals ADR 2,50 9,600 PATLAB Dispharmaceuticals ADR 2,50 9,600 PATLAB Dispharmaceutical ADR 1,50 79,55 PATLAB Dispharmaceutical ADR 1,50 79,55 PATLAB Dispharmaceutical ADR 1,50 79,55 PATLAB DISPHARMACEUTICA ADR 1,10 22,58 PATLAB DISPHARMACEUTICA ADR 1,10 48,61 Glaxos Burbano 1,70 10,93 Glaxos Burbano 1,00 37,60 Marcel 1,00 37,60 Marcel 1,00 37,60 Marcel 1,00 38,52 Glaxos Burbano 1,0			
Scaramp Pharmaceuticals Class A 2,500 2,6825 Synta Pharmaceuticals 900 5,590 17 Tubolon Pharmaceuticals 1,600 7,136 Panda Pharmaceuticals 2,000 6,880 Panda Pharmaceuticals ADR 2,500 9,600 15 Tubolon Pharmaceuticals ADR 1,500 12,630 15 Tubolon Pharmaceuticals ADR 1,500 7,800 15 Word Chip Medical Products - 37,58% 3,200 15,901 Abbot Laborativies 1,500 7,945 Arangen 3,200 15,901 Atara James 7,98 14,049 Atara James eutical 4,022 45,366 Giones Markh Kine ADR 1,100 48,642 Giones Markh Kine ADR 1,00 37,690 Medicionic 1,200 62,100 Merck 1,00 37,690 Morantis ADR 1,00 37,690 Morantis ADR 2,21 3,980 Fibrar 5,00 8,730 Wick 6,00 2,820			
Synta Pharmaceuticals 900 5,490 Fitan Pharmaceuticals 700 966 Fitan Pharmaceuticals 2,000 6,880 FVATI Biopharmaceuticals 2,000 6,880 EVIT Biopharmaceuticals ADR 2,000 9,000 EVIT Biopharmaceuticals ADR 2,000 9,000 EVIT Biopharmaceuticals ADR 1,000 20,200 Biocal Applications of Type Admitical Products of 37,58% 1,500 79,455 Abhort Laboritaries 1,500 79,455 Affangen 3,200 150,911 Astatz-Greeca 788 34,049 Bristol-Myers Squibb 1,100 22,583 Chapia Pharmaceutical 4,022 64,366 Glementech 800 67,200 Glementech 1,00 34,642 Johnson & Johnson 1,100 48,642 Johnson & Johnson 1,00 37,800 Novatris ADR 70 38,282 Pitzer 5,00 37,800 Novatris ADR 75 63,200			
Fit Info Pharmaceuticals 700 96 Fit Tubion Pharmaceuticals 1,600 7,136 YANDA Pharmaceuticals 2,000 6,800 FYTL Biopharmaceuticals ADR 2,000 9,000 EZYM DeGenetics 1,500 12,630 EZYM DeGenetics 1,500 79,455 Biology Degeneration 1,500 79,455 Brown Chip Medical Products - 37,33% 30,000 15,000 79,455 Plangen 3,200 15,011 31,001 22,833 Abustiz-Decension 1,100 22,833 36,000 36,026 Bristol-Myers Squibb 1,100 22,833 36,000 36,026 36,000 36,026 36,000 36,026 36,000 36,026 36,000 36,026 36,000 36,026 36,000 36,026 36,000 36,026 36,000 36,026 36,000 36,026 36,000 36,026 36,000 36,026 36,000 36,000 36,000 36,000 36,000 36,000 36,000 36,000 36,000 <td></td> <td>·</td> <td></td>		·	
Probine Pharmaceuticals 1,600 7,136 Plance Pharmaceuticals 2,000 6,808 EXTL Biopharmaceuticals ADR 2,500 9,600 EXTL Biopharmaceuticals ADR 1,500 12,600 Logonometrics 1,500 79,455 Abbort Laboratories 1,500 79,455 Abbort Laboratories 3,00 15,901 Astracence 798 3,409 British Alpers Squibb 1,100 22,583 Chlegai Pharmaceutical 4,022 64,366 Glossos MithKline ADR 1,100 48,642 Glossos Schönson 1,100 48,642 Hoffstonic 1,00 37,500 Moratis ADR 7,00 38,528 Prizer 5,00 37,300 Samifi-Aventis 79 43,16 Skill-Judy Medical 221 39,806 Skill-Judy Medical 221 3,316 Skill-Judy Medical 221 3,316 Skill-Judy Medical 49,22 43,316 Skill-Judy M	· ·		
Wanda Pharmaceuticals 2,000 6,580 EXTL Biopharmaceuticals ADR 2,500 9,600 EXTL Biopharmaceuticals 1,500 12,630 Expression 1,500 79,455 Abbout Laboratorics 1,500 79,455 Famgen 3,200 15,911 Astrazenca 3,200 61,091 Kintzele 4,022 64,366 Generich 800 60,720 Giacosmithkline ADR 1,100 48,642 Ioliuson & Johnson 1,100 48,642 Ioliuson & Johnson 1,000 37,690 Noverla 1,000 37,690 Noverla ADR 7,00 38,238 Rockel Holding 221 39,806 Sanofi-Awetis 754 50,372 Smith & Nephew 4,922 54,316 Weyen 900 21,528 Healtheare 2,100 1,527 Healtheare 2,100 1,527 Healtheare 1,200 6,814			
EXTL Biopharmaceuticals ADR 2,500 9,600 IZymoGenetics 1,500 12,630 Biopharmaceuticals 1,500 79,455 Biopharmaceutical Products - 37,58% 1,500 79,455 Adargen 3,200 150,911 Astra-Greca 798 31,409 Existed-Myers Squibb 1,100 22,533 Clugai Pharmaceutical 4,022 64,366 Genench 80 69,720 Glasso Smith Kline ADR 1,100 48,642 Medicionic 1,200 62,100 Merck 1,200 62,100 Moratis ADR 1,00 38,528 Movartis ADR 1,00 38,528 Rocke Holding 221 39,806 Sanofi-A wetts 5,00 38,328 Simité A Nephew 4,922 34,164 Sill Judy Medical 4,922 34,164 Weyth 90 43,164 Sill Judy Medical 4,922 34,164 Weyth 1,00 48,242			
1,500 1,203 1,20		·	
Substitution Subs			
Blue Cinp Medical Products - 37.58% Abbott Laboratories 1,500 79,455 Abgen 3,200 150,911 AstraZencea 798 34,049 Bristol-Myers Squibb 1,100 22,858 Chugai Pharmaceutical 4,022 64,366 Genencech 800 60,720 Glaxos MithKline ADR 1,100 48,642 Johnson & Johnson 1,700 199,378 Meditonic 1,200 62,100 Merek 1,000 37,569 Novartis ADR 700 38,528 Pfizer 5,000 87,350 Sanofi-Aventis 754 50,372 Smith & Nephew 4,922 54,316 %E. Jude Medicial 49,22 54,316 %E. Jude Medicial 600 24,528 Wyeth 900 43,164 %E. Jude Medicial 700 14,252 %E. Jude Medicial 700 14,252 %E. Jude Medicial 700 14,252 Well Medicial 1,2	ZymoGenetics	1,500	
Abbott Laboratories 1,500 79,455 Amegen 3,200 150,911 Astra-Cencea 798 34,049 Pristol-Myers Squibb 1,100 22,588 Chingai Pharmaceutical 800 60,720 Genentech 800 60,720 Glaxo Smith Kline ADR 1,100 48,642 Johnson & Johnson 1,700 62,100 Metrock 1,000 37,590 Metrok 7,00 38,528 Prizer 5,000 87,350 Roche Holding 221 39,806 Samofi-Aventis 754 5,372 Smith & Nephew 4,922 54,316 Str. Jude Medicial 600 24,228 Wyeth 90 4,316 Str. Jude Medicial 70 1,202 Wyeth 90 4,316 Str. Jude Medicial 70 1,202 Wyeth 90 4,316 Prizer 1,200 2,828 Brouklade Senior Living			540,727
Famour 3,200 150,911 AstraZencea 798 34,049 Beristol-Myers Squibb 1,100 22,838 Chugai Pharmaceutical 4,022 64,366 Generated 800 60,720 Glaxo Smith Kline ADR 1,100 48,642 Johnson & Johnson 1,700 109,378 Meditronic 1,200 62,100 Merck 1,000 37,569 Novartis ADR 700 38,528 Prizer 5,000 87,350 Roche Holding 221 39,806 Samifa Nephew 4,922 54,316 Str. Jud Medical 4,922 54,316 Str. Jud Medical 600 24,528 Wyeth 90 43,164 Str. Jud Medical 700 14,252 Wyeth 90 43,164 Str. Jud Medical 700 12,207 Health care Services - 14,14% 70 12,207 Pical Medical Senior Living 70 12,207			
AstraZeneca 798 34,049 Bristol-Myers Squibb 1,100 22,583 Chugai Pharmaceutical 4,022 64,366 Genetech 800 60,700 Glaxo Smith Kline ADR 1,100 48,64 Johnson & Johnson 1,700 19,378 Merck 1,000 37,690 Merck 1,000 37,500 Novartis ADR 700 38,528 Pfizer 5,000 87,350 Roche Holding 221 39,806 Smofti-Aventis 754 50,325 Smith & Nephew 4,922 54,316 Fist Jude Medical 600 24,528 Wyeth 900 43,164 Weth 90 43,164 Plaity-Scruices - 14,14% 700 12,252 Brokale Senior Living 70 12,252 Outs Diagnostics 1,200 58,164 Veriation Senior Living 300 6,744 United Health Group 4,850 127,313			
Bristol-Myers Squibb 1,100 22,583 Chugai Pharmaceutical 4,022 64,366 Feenetech 800 60,720 Glaxo SmithKline ADR 1,100 48,642 Johnson & Johnson 1,700 109,378 Medtronic 1,200 62,100 Merck 1,000 37,690 Novartis ADR 700 38,528 Prizer 5,000 87,350 Roche Holding 221 39,806 Sanofi-Aventis 754 50,372 Smith & Nephew 4,922 54,316 Y85. Jude Medical 600 24,528 Wyeth 900 43,164 Healthcare Services - 14,14% 700 12,252 Brookdale Senior Living 700 12,252 Pilaghis Corp. of America 1,200 28,872 Quest Diagnostics 1,200 58,164 Sunrise Senior Living 300 6,744 UnitedHealth Group 4,850 127,313 WellPoint 2,700			
Chugai Pharmaceutical 4,022 64,366 Genentech 800 60,720 Glaxo Smith Kline ADR 1,100 48,642 Johnson & Johnson 1,700 109,378 Medronic 1,000 62,100 Merck 1,000 37,500 Movartis ADR 700 38,528 Novartis ADR 700 87,350 Roche Holding 221 39,806 Sanoff-Aventis 754 50,372 Smith & Nephew 4,922 54,316 %St. Jude Medical 600 24,528 Wyeth 90 43,164 Brookdale Senire Living 70 14,252 Pilolaysis Corp. of America 2,100 15,267 Brookdale Senire Living 70 14,252 Pilolaysis Corp. of America 1,200 28,872 Quest Diagnostics 1,200 28,872 Well Diagnostics 1,200 58,164 WulliedHealth Group 4,850 127,313 Well Diagnostics 2,700 12,868			
Genentech 800 60,720 GlaxoSmithKline ADR 1,100 48,642 Johnson & Johnson 1,700 109,378 Medtronic 1,200 62,100 Merck 1,000 37,690 Novartis ADR 70 38,528 Pfizer 5,000 87,350 Roche Holding 221 39,806 Sanoff-Aventis 754 50,372 Smith & Nephew 4,922 54,316 %t Jude Medical 600 24,528 Wyeth 90 43,164 Weth 700 14,252 Eloukale Senior Living 700 14,252 Floallysis Corp. of America 2,100 15,267 Flealth Net 1,200 28,872 Quest Diagnostics 1,200 58,164 % Sunrise Senior Living 300 6,744 United Health Group 4,850 127,313 WellPoint 2,700 128,682	· · ·	·	•
GlaxoSmithKline ADR 1,100 48,642 Johnson & Johnson 1,700 199,378 Medtronic 1,200 62,100 Merck 1,000 37,690 Novartis ADR 700 38,528 Pfizer 5,000 87,350 Roche Holding 221 39,806 Sanoff-Aventis 754 50,372 Smith & Nephew 4,922 54,316 %St. Jude Medical 600 24,528 Wyeth 600 24,528 Wyeth 50,000 10,000 Health Acer Services - 14,14% 700 12,522 Pladysis Corp. of America 2,100 15,267 Pladysis Corp. of America 2,100 15,267 Pladysis Corp. of America 1,200 28,872 Quest Diagnostics 1,200 58,164 *Sunrise Senior Living 300 6,744 United Health Group 4,850 127,313 *WellPoint 2,700 128,682			
Johnson & Johnson 1,700 109,378 Meddronic 1,200 62,100 Merck 1,000 37,690 Novartis ADR 700 38,528 Pfizer 5,000 87,350 Roche Holding 221 39,806 Sanofi-Aventis 754 50,372 Smith & Nephew 4,922 54,316 †St. Jude Medical 600 24,528 Wyeth 900 43,164 Healthcare Services - 14,14% 700 14,252 Ploilysis Corp. of America 2,100 15,267 †Belath Net 1,200 28,872 Quest Diagnostics 1,200 58,164 *Sunrise Senior Living 300 6,744 United Health Group 4,850 127,313 *WellPoint 2,700 128,682			,
Meditronic 1,200 62,100 Merck 1,000 37,690 Novartis ADR 700 38,528 Pfizer 5,000 87,350 Roche Holding 221 39,806 Sanoff-Aventis 754 50,372 Smith & Nephew 4,922 54,316 †St. Jude Medical 600 24,528 Wyeth 900 43,164 Health Care Services - 14,14% 700 14,252 Probable Senior Living 700 14,252 †Dialysis Corp. of America 2,100 15,267 Plealth Net 1,200 28,872 Quest Diagnostics 1,200 58,164 *Sunrise Senior Living 300 6,744 United Health Group 4,850 127,313 WellPoint 2,700 128,682		1,100	
Merck 1,000 37,690 Novartis ADR 700 38,528 Pfizer 5,000 87,350 Roche Holding 221 39,806 Sanofi-Aventis 754 50,372 Smith & Nephew 4,922 54,316 *St. Jude Medical 600 24,528 Wyeth 900 43,164 Healthcare Services - 14.14% 8 1,007,95 Health Services - 14.14% 2,100 15,267 *Plailysis Corp. of America 2,100 15,267 *Pleasth Net 1,200 28,872 Quest Diagnostics 1,200 58,164 *Sunrise Senior Living 300 6,744 United Health Group 4,850 127,313 *EvellPoint 2,700 128,682	Johnson & Johnson		
Novartis ADR 700 38,528 Pfizer 5,000 87,350 Roche Holding 221 39,806 Sanofi-Aventis 754 50,372 Smith & Nephew 4,922 54,316 *St. Jude Medical 600 24,528 Wyeth 900 43,164 Healthcare Services - 14,14% 8 700 14,252 Brookdale Senior Living 700 14,252 15,267 <td>Medtronic</td> <td></td> <td></td>	Medtronic		
Pfizer 5,000 87,350 Roche Holding 221 39,806 Sanofi-Aventis 754 50,372 Smith & Nephew 4,922 54,316 *St. Jude Medical 600 24,528 Wyeth 900 43,164 Weth 900 43,164 Brookdale Senior Living 700 14,252 *Flealth Net 1,200 28,872 Quest Diagnostics 1,200 58,164 *Sunrise Senior Living 300 6,744 UnitedHealth Group 4,850 127,313 *WellPoint 2,700 128,682	Merck	1,000	37,690
Roche Holding 221 39,806 Sanofi-Aventis 754 50,372 Smith & Nephew 4,922 54,316 YSt. Jude Medical 600 24,528 Wyeth 900 43,164 Health care Services - 14.14% 1,007,95 Health Care Services - 14.14% 2,100 15,267 Fleath Net 1,200 28,872 Quest Diagnostics 1,200 58,164 YSunrise Senior Living 300 6,744 UnitedHealth Group 4,850 127,313 YWellPoint 2,700 128,682	Novartis ADR	700	38,528
Sanofi-Aventis 754 50,372 Smith & Nephew 4,922 54,316 Smith & Nephew 600 24,528 Wyeth 900 43,164 Healthcare Services - 14.14% 1,007,95 Healthcare Services - 14.14% 700 14,252 Prookdale Senior Living 700 15,267 Flealth Net 1,200 28,872 Quest Diagnostics 1,200 58,164 Sunrise Senior Living 300 6,744 UnitedHealth Group 4,850 127,313 WellPoint 2,700 128,682	Pfizer	5,000	87,350
Smith & Nephew 4,922 54,316 Smith & Nephew 600 24,528 Wyeth 900 43,164 Healthcare Services - 14.14% 700 14,252 Brookdale Senior Living 700 14,252 Polialysis Corp. of America 2,100 15,267 Health Net 1,200 28,872 Quest Diagnostics 1,200 58,164 Sunrise Senior Living 300 6,744 UnitedHealth Group 4,850 127,313 WellPoint 2,700 128,682	Roche Holding	221	39,806
† St. Jude Medical 600 24,528 Wyeth 900 43,164 Healthcare Services - 14.14% 1,007,95 Brookdale Senior Living 700 14,252 † Dialysis Corp. of America 2,100 15,267 † Health Net 1,200 28,872 Quest Diagnostics 1,200 58,164 † Sunrise Senior Living 300 6,744 UnitedHealth Group 4,850 127,313 † WellPoint 2,700 128,682	Sanofi-Aventis	754	50,372
Wyeth 900 43,164 1,007,95 Healthcare Services - 14.14% 700 14,252 Brookdale Senior Living 700 15,267 Health Net 1,200 28,872 Quest Diagnostics 1,200 58,164 Sunrise Senior Living 300 6,744 United Health Group 4,850 127,313 WellPoint 2,700 128,682	Smith & Nephew	4,922	54,316
1,007,95 Healthcare Services - 14.14% Brookdale Senior Living 700 14,252 Dialysis Corp. of America 2,100 15,267 Health Net 1,200 28,872 Quest Diagnostics 1,200 58,164 Sunrise Senior Living 300 6,744 United Health Group 4,850 127,313 WellPoint 2,700 128,682	†St. Jude Medical	600	24,528
Healthcare Services - 14.14% Brookdale Senior Living 700 14,252 † Dialysis Corp. of America 2,100 15,267 † Health Net 1,200 28,872 Quest Diagnostics 1,200 58,164 † Sunrise Senior Living 300 6,744 UnitedHealth Group 4,850 127,313 † WellPoint 2,700 128,682	Wyeth	900	43,164
Brookdale Senior Living 700 14,252 † Dialysis Corp. of America 2,100 15,267 † Health Net 1,200 28,872 Quest Diagnostics 1,200 58,164 † Sunrise Senior Living 300 6,744 UnitedHealth Group 4,850 127,313 † WellPoint 2,700 128,682			1,007,958
† Dialysis Corp. of America 2,100 15,267 † Health Net 1,200 28,872 Quest Diagnostics 1,200 58,164 † Sunrise Senior Living 300 6,744 UnitedHealth Group 4,850 127,313 † WellPoint 2,700 128,682	Healthcare Services - 14.14%		
† Dialysis Corp. of America 2,100 15,267 † Health Net 1,200 28,872 Quest Diagnostics 1,200 58,164 † Sunrise Senior Living 300 6,744 UnitedHealth Group 4,850 127,313 † WellPoint 2,700 128,682	Brookdale Senior Living	700	14,252
† Health Net 1,200 28,872 Quest Diagnostics 1,200 58,164 † Sunrise Senior Living 300 6,744 UnitedHealth Group 4,850 127,313 † WellPoint 2,700 128,682	†Dialysis Corp. of America	2,100	
Quest Diagnostics 1,200 58,164 †Sunrise Senior Living 300 6,744 UnitedHealth Group 4,850 127,313 †WellPoint 2,700 128,682	†Health Net		
† Sunrise Senior Living 300 6,744 UnitedHealth Group 4,850 127,313 † WellPoint 2,700 128,682	Quest Diagnostics		
UnitedHealth Group 4,850 127,313 †WellPoint 2,700 128,682			
†WellPoint 2,700 <u>128,682</u>			
<u> </u>			
			379,294

Small/Mid-Cap Medical Products - 23.96%		
†Accuray	1,800	13,122
†Affymetrix	2,100	21,609
†Applera - Celera Group	2,000	22,720
†Barr Pharmaceuticals	2,250	101,429
Bayer	378	31,746
†Bio-Rad Laboratories Class A	200	16,178
Koninklijke	890	52,367
†Luminex	700	14,385
†Noven Pharmaceuticals	2,600	27,794
†Par Pharmaceutical	2,000	32,460
Perrigo	1,000	31,770
†ResMed	500	17,870
†Sepracor	2,000	39,840
†Sequenom	5,300	84,588
†Sorin	3,300	4,157
Taisho Pharmaceutical	3,000	55,640
†Watson Pharmaceuticals	650	17,661
West Pharmaceutical Services	600	25,968
†Wright Medical Group	1,100	31,251
		642,555
Total Common Stock (cost \$2,691,676)		2,570,53
Total Value of Securities - 95.84%		
(cost \$2,691,676)		2,570,53
Receivables and Other Assets Net of Liabilities (See Notes) - 4.16%		111,606
Net Assets Applicable to 335,768 Shares Outstanding - 100.00%		\$2,682,14

†Non income producing security.

□Narrow industries are utilized for compliance purposes for diversification whereas broad sectors are used for financial reporting.

ADR - American Depositary Receipt

Notes

1. Significant Accounting Policies

The following accounting policies are in accordance with U.S. generally accepted accounting principles and are consistently followed by Delaware Group Equity Funds IV - Delaware Healthcare Fund (Fund).

Security Valuation - Equity securities, except those traded on the Nasdaq Stock Market, Inc. (Nasdaq), are valued at the last quoted sales price as of the time of the regular close of the New York Stock Exchange (NYSE) on the valuation date. Securities traded on the Nasdaq are valued in accordance with the Nasdaq Official Closing Price, which may not be the last sales price. If on a particular day an equity security does not trade, then the mean between the bid and asked prices will be used. Securities listed on a foreign exchange are valued at the last quoted sales price on the valuation date. Short-term debt securities having less than 60 days to maturity are valued at amortized cost, which approximates market value. Generally, other securities and assets for which market quotations are not readily available are valued at fair value as determined in good faith under the direction of the Fund's Board of Trustees (Board). In determining whether market quotations are readily available or fair valuation will be used, various factors will be taken into consideration, such as market closures, or with respect to foreign securities, aftermarket trading or significant events after local market trading (e.g., government actions or pronouncements, trading volume or volatility on markets, exchanges among dealers, or news events).

In September 2006, the Financial Accounting Standards Board (FASB) issued FASB Statement No. 157, "Fair Value Measurements" (Statement 157). Statement 157 establishes a framework for measuring fair value in U.S. generally accepted accounting principles, clarifies the definition of fair value within that framework, and expands disclosures about the use of fair value measurements. Statement 157 is intended to increase consistency and comparability among fair value estimates used in financial reporting. Statement 157 is effective for fiscal years beginning after November 15, 2007. Management does not expect the adoption of Statement 157 to have an impact on the amounts reported in the financial statements.

Federal Income Taxes - The Fund intends to qualify for federal income tax purposes as a regulated investment company under Subchapter M of the Internal Revenue Code of 1986, as amended, and make the requisite distributions to shareholders. Accordingly, no provision for federal income taxes has been made in the financial statements.

Class Accounting - Investment income, common expenses and realized and unrealized gain (loss) on investments are allocated to the various classes of the Fund on the basis of daily net assets of each class. Distribution expenses relating to a specific class are charged directly to that class.

Repurchase Agreements - The Fund may invest in a pooled cash account along with other members of the Delaware Investments. Family of Funds pursuant to an exemptive order issued by the Securities and Exchange Commission. The aggregate daily balance of the pooled cash account is invested in repurchase agreements secured by obligations of the U.S. government. The respective collateral is held by the Fund's custodian bank until the maturity of the respective repurchase agreements. Each repurchase agreement is at least 102% collateralized. However, in the event of default or bankruptcy by the counterparty to the agreement, realization of the collateral may be subject to legal proceedings. At June 30, 2008, the Fund held no investments in repurchase agreements.

Use of Estimates – The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Other – Expenses directly attributable to the Fund are charged directly to the Fund. Other expenses common to various funds within the Delaware Investments. Family of Funds are generally allocated amongst such funds on the basis of average net assets. Management fees and some other expenses are paid monthly. Security transactions are recorded on the date the securities are purchased or sold (trade date) for financial reporting purposes. Costs used in calculating realized gains and losses on the sale of investment securities are those of the specific securities sold. Dividend income is recorded on the ex-dividend date and interest income is recorded on the accrual basis. Foreign dividends are also recorded on the ex-dividend date or as soon after the ex-dividend date that the Fund is aware of such dividends, net of all non-rebatable tax withholdings. Withholding taxes on foreign dividends have been recorded in accordance with the Fund's understanding of the applicable country's tax rules and rates. The Fund declares and pays dividends from net investment income and distributions from net realized gain on investments, if any, annually.

2. Investments

At June 30, 2008, the cost of investments for federal income tax purposes has been estimated since final tax characteristics cannot be determined until fiscal year end. At June 30, 2008, the cost of investments and unrealized appreciation (depreciation) for the Fund were as follows:

Cost of investments	\$2,698,060
Aggregate unrealized appreciation	\$132,704
Aggregate unrealized depreciation	(260,230)
Net unrealized depreciation	\$(127,526)

3. Credit and Market Risk

The Fund invests a significant portion of its assets in small companies and may be subject to certain risks associated with ownership of securities of such companies. Investments in small-sized companies may be more volatile than investments in larger companies for a number of reasons, which include limited financial resources or a dependence on narrow product lines.

Some countries in which the Fund may invest require governmental approval for the repatriation of investment income, capital or the proceeds of sales of securities by foreign investors. In addition, if there is deterioration in a country's balance of payments or for other reasons, a country may impose temporary restrictions on foreign capital remittances abroad.

The securities exchanges of certain foreign markets are substantially smaller, less liquid, and more volatile than the major securities markets in the United States. Consequently, acquisition and disposition of securities by the Fund may be inhibited. In addition, a significant portion of the aggregate market value of equity securities listed on the major securities exchanges in emerging markets are held by a smaller number of investors. This may limit the number of shares available for acquisition or disposition by the Fund.

The Fund concentrates its investments in the healthcare industry and is subject to some of the risks associated with that industry. The value of the Fund's shares will be affected by factors particular to the healthcare and related sectors (such as government regulation) and may fluctuate more widely than that of a fund which invests in a broad range of industries.

The Fund may invest up to 15% of its net assets in illiquid securities, which may include securities with contractual restrictions on resale, securities exempt from registration under Rule 144A of the Securities Act of 1933, as amended, and other securities which may not be readily marketable. The relative illiquidity of these securities may impair the Fund from disposing of them in a timely manner and at a fair price when it is necessary or desirable to do so. While maintaining oversight, the Fund's Board has delegated to Delaware Management Company, a series of Delaware Management Business Trust, the day-to-day functions of determining whether individual securities are liquid for purposes of the Fund's limitation on investments in illiquid assets. Securities eligible for resale pursuant to Rule 144A, which are determined to be liquid, are not subject to the Fund's 15% limit on investments in illiquid securities. At June 30, 2008, there were no Rule 144A securities and no securities have been determined to be illiquid under the Fund's Liquidity Procedures.

Item 2. Controls and Procedures.

The registrant's principal executive officer and principal financial officer have evaluated the registrant's disclosure controls and procedures within 90 days of the filing of this report and have concluded that they are effective in providing reasonable assurance that the information required to be disclosed by the registrant in its reports or statements filed under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission.

There were no significant changes in the registrant's internal control over financial reporting that occurred during the registrant's last fiscal quarter that have materially affected, or are reasonably likely to materially affect, the registrant's internal control over financial reporting.

Item 3. Exhibits.

File as exhibits as part of this Form a separate certification for each principal executive officer and principal financial officer of the registrant as required by Rule 30a-2(a) under the Act (17 CFR 270.30a-2(a)), exactly as set forth below:

CERTIFICATION

I, Patrick P. Coyne, certify that:

- 1. I have reviewed this report on Form N-Q of Delaware Group Equity Funds IV;
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the schedules of investments included in this report fairly present in all material respects the investments of the registrant as of the end of the fiscal quarter for which the report is filed;
- 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this report, based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer(s) and I have disclosed to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

PATRICK P. COYNE

By: Patrick P. Coyne

Title: Chief Executive Officer

Date: August 29, 2008

CERTIFICATION

I, Richard Salus, certify that:

- 1. I have reviewed this report on Form N-Q of Delaware Group Equity Funds IV;
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the schedules of investments included in this report fairly present in all material respects the investments of the registrant as of the end of the fiscal quarter for which the report is filed;
- 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this report, based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer(s) and I have disclosed to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

RICI	HARD SALUS	
Bv·	Richard Salus	

Title: Chief Financial Officer Date: August 29, 2008

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

DELAWARE GROUP EQUITY FUNDS IV

PATRICK P. COYNE

By: Patrick P. Coyne

Title: Chief Executive Officer Date: August 29, 2008

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

PATRICK P. COYNE

By: Patrick P. Coyne

Title: Chief Executive Officer

Date: August 29, 2008

RICHARD SALUS

By: Richard Salus

Title: Chief Financial Officer Date: August 29, 2008